

Table 14-4.01
Summary of Planned Exposure to Study Drug, as of End of Study

		Completers at Week 24			Safety Population [1]		
		Placebo (N=60)	Xanomeline Low Dose (N=28)	Xanomeline High Dose (N=30)	Placebo (N=86)	Xanomeline Low Dose (N=84)	Xanomeline High Dose (N=84)
Average daily dose (mg)	n	60	28	30	86	84	84
	mean	0.0	54.0	77.0	0.0	54.0	71.6
	std	0.00	0.00	0.58	0.00	0.00	8.11
	median	0.0	54.0	76.9	0.0	54.0	75.1
	min	0.0	54.0	76.1	0.0	54.0	54.0
	max	0.0	54.0	78.6	0.0	54.0	78.6
Cumulative dose at end of study [2]	n	60	28	30	86	84	84
	mean	0.0	9918.6	14089.5	0.0	5347.3	7551.0
	std	0.00	603.84	481.01	0.00	3680.35	5531.04
	median	0.0	9936.0	14080.5	0.0	4455.0	5778.0
	min	0.0	7884.0	12960.0	0.0	108.0	54.0
	max	0.0	11448.0	15417.0	0.0	11448.0	15417.0

[1] Includes completers and early terminators.

[2] End of Study refers to week 26/Early Termination.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\adsl12.sas

21:02 Monday, June 26, 2006